Table 1.
Study (month year) | Country | No. of patients | Age (median, years) | Sex males | HTN | DM | Other comorbidities | ACEI/ARB usage |
---|---|---|---|---|---|---|---|---|
Meng et al. (March 2020) | China | 417 | 64.5* (IQR = 55.8–69.0) | 24* | 42† | 6* | 17* | |
Richardson et al. (April 2020) | USA | 5700 | 63 (IQR = 52–75) | 3437 | 3026 | 1808 |
|
413‡ |
Li et al. (April 2020) | China | 1178 | 55.5 (IQR = 38–67) | 545 | 362 | 203 |
|
115* |
Liu et al. (March 2020) | China | 511 | 65.2 (mean) (SE = 10.7)* | 43* | 78 | NA | NA | 22* |
Zhang et al. (April 2020) | China | 3430 | 57 (IQR = 45–65) | 1675 | 1128 | 388 |
|
188* |
Feng et al. (April 2020) | China | 476 | 53 (IQR = 40–64) | 271 | 113 | 49 |
|
33* |
Guo et al. (March 2020) | China | 187 | 58.50 (mean) (SD = 14.66) | 91 | 61 | 28 |
|
19 |
Bean et al. (April 2020) | UK | 205 | 62.95 (mean) (SD = 19.94) | 106 | 105 | 62 | CAD/HF: 30 | 46 |
Yang et al. (April 2020) | China | 251 | 66 (IQR = 61–73)* | 62* | 126 | 55 |
|
43 |
Zeng et al. (April 2020) | China | 274 | 60 (mean) (SD = 15) | 150 | 75 | 42 |
|
28* |
Ip et al. (April 2020) | USA | 3017 | NA | NA | 1584 | NA | NA | 460 |
Yan et al. (April 2020) | China | 49 277 | 48.75§ (mean) (SD = 14.19) | 311§ | 137 | 60 | CD/CVD: 16 | 58 |
Mancia et al. (May 2020) | Italy | 37 031 | 68 (mean) (SD = 13) | 23 329 | NA | NA |
|
15 375 |
Mehra et al. (May 2020) | Asia, Europe, North America | 8910 | 49 (mean) (SD = 16) | 5346 | 2346 | 1272 | COPD: 225 | 1326 |
Reynolds et al. (May 2020) | USA | 12 594¶ | 49 (IQR = 34 –63) | 5226 | 4357 | 2271 |
|
1110 |
Dauchet et al. (May 2020) | France | 288** | NA | 179 | 105†† | 40 |
|
62‡‡ |
HTN, hypertension; DM, diabetes mellitus; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IQR, interquartile range; CHD, coronary heart disease; AV block, atrioventricular block; CAD, coronary artery disease; HF, heart failure; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; CVD, cerebrovascular disease; SE, standard error; NA, not applicable; CD, cardiovascular disease; SD, standard deviation; RD, respiratory disease; KD, kidney disease, MI, myocardial infarction.
Reported for hypertensive patients.
Nine out of total 51 hypertensive patients were excluded in subsequent analysis because they were not on any antihypertensive drugs during hospitalization.
Home medication reconciliation information was available for 2411 of the 2634 patients who were discharged or who died by the study end.
Calculated for 610 COVID 19 patients out of total of 49 277.
Patients tested for COVID-19.
Patients aged over 35 years suspected of or diagnosed with COVID-19.
Patients on antihypertensive treatment.
Reported for COVID-19-positive patients (187 out of 288 suspected of or diagnosed patients).